Duktal Karsinoma İn Situ
Özet
Duktal karsinoma in situ (DKİS), meme duktal - lobüler ünitesinde bazal membranı aşmadan sınırlı kalan, farklı histopatolojik özellikler sergileyebilen heterojen bir neoplastik proliferasyondur. Mamografinin yaygın kullanımıyla birlikte DKİS insidansında belirgin bir artış gözlenmiş ve günümüzde yeni teşhis edilen meme kanserlerinin yaklaşık dörtte birini oluşturmaktadır. DKİS tedavisinde temel hedef, invaziv meme kanserine dönüşüm riskini en aza indirmektir. Bu amaçla cerrahi, radyoterapi ve adjuvan endokrin tedavi gibi çeşitli yaklaşımlar uygulanmaktadır.
Referanslar
Lakhani SR, Ellis IO, Schnitt SJ et al., editors. WHO/IARC Classi fication of Tumours of the Breast. 4th ed, Vol 4. Lyon, France: World Health Organization (WHO), International Agency for Research on Cancer (IARC); 2012.,
Grimm LJ, Rahbar H, Abdelmalak M, Hall AH, Ryser MD. Ductal Carcinoma in Situ: State-of-the-Art Review. Radiology. 2022 Feb;302(2):246-255. doi: 10.1148/radiol.211839. Epub 2021 Dec 21.
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17. Erratum in: CA: A Cancer Journal for Clinicians. 2024 Mar-Apr;74(2):203. doi: 10.3322/caac.21830.
Kerlikowske K. Epidemiology of ductal carcinoma in situ. Journal of the National Cancer Institute Monographs. 2010;2010(41):139-41. doi: 10.1093/jncimonographs/lgq027.
Kerlikowske K, Barclay J, Grady D, et al. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. Journal of the National Cancer Institute. 1997 Jan 1;89(1):76-82. doi: 10.1093/jnci/89.1.76.
Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. Journal of the National Cancer Institute. 2010 Feb 3;102(3):170-8. doi: 10.1093/jnci/djp482. Epub 2010 Jan 13.
Richards T, Hunt A, Courtney S, Umeh H. Nipple discharge: a sign of breast cancer? Annals of the Royal College of Surgeons of England. 2007 Mar;89(2):124-6. doi: 10.1308/003588407X155491.
Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet. 2007 Aug 11;370(9586):485-92. doi: 10.1016/S0140-6736(07)61232-X.
Esserman LJ, Kumar AS, Herrera AF, et al. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. Journal of Clinical Oncology. 2006 Oct 1;24(28):4603-10. doi:10.1200/JCO.2005.04.5518.
10.White RR, Halperin TJ, Olson JA Jr, et al. Impact of core-needle breast biopsy on the surgical management of mammographic abnormalities. Annals of Surgery. 2001 Jun;233(6):769-77. doi: 10.1097/00000658-200106000-00006.
Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer. 1997 Nov 1;80(9):1798-802. doi: 10.1002/(sici)1097-0142(19971101)80:9<1798::aid-cncr15>3.0.co;2-0.
Melody A. Cobleigh et al. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. Journal of Clinical Oncology. 39, 2367-2374(2021). DOI:10.1200/JCO.20.02824
13.Stackievicz R, Paran H, Bernheim J, et al. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ. The Israel Medical Association Journal. 2010 May;12(5):290-5.
Kuerer HM, Albarracin CT, Yang WT, et al. Ductal Carcinoma in Situ: State of the Science and Roadmap to Advance the Field. Journal of Clinical Oncology. 27, 279-288(2009 Jan). doi: 10.1200/JCO.2008.18.3103.
Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. Journal of the National Cancer Institute. 2011 Mar 16;103(6):478-88. doi: 10.1093/jnci/djr027. Epub 2011 Mar 11.
Rakovitch E, Pignol JP, Hanna W, et al. Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. Journal of Clinical Oncology. 2007 Dec 10;25(35):5591-6. doi: 10.1200/JCO.2007.11.4686. Epub 2007 Nov 5.
Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. Annals of Surgical Oncology. 2016 Nov;23(12):3801-3810. doi: 10.1245/s10434-016-5449-z. Epub 2016 Aug 15.
Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. The New England Journal of Medicine. 1999 May 13;340(19):1455-61. doi: 10.1056/NEJM199905133401902.
Ernster VL, Barclay J, Kerlikowske K, et al. Mortality Among Women With Ductal Carcinoma In Situ of the Breast in the Population-Based Surveillance, Epidemiology and End Results Program. Archives of Internal Medicine. 2000;160(7):953–958. doi:10.1001/archinte.160.7.953
Lara JF, Young SM, Velilla RE, et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer. 2003 Nov 15;98(10):2105-13. doi: 10.1002/cncr.11761.
Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. Journal of the National Cancer Institute. 2010 Feb 3;102(3):170-8. doi: 10.1093/jnci/djp482. Epub 2010 Jan 13.
Li, P.C., Punglia, R.S. DCIS: Radiation Considerations. Current Breast Cancer Reports. 12, 75–81 (2020). https://doi.org/10.1007/s12609-020-00357-0
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast, Journal of the National Cancer Institute. Monographs. Volume 2010, Issue 41, October 2010, Pages 162-177, https://doi.org/10.1093/jncimonographs/lgq039
Gilleard O, Goodman A, Cooper M, et al. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World Journal of Surgical Oncology. 2008 Jun 18;6:61. doi: 10.1186/1477-7819-6-61.
25.Sagara Y, Freedman RA, Vaz-Luis I, et al. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. Journal of Clinical Oncology. 2016 Apr 10;34(11):1190-6. doi: 10.1200/JCO.2015.65.1869. Epub 2016 Feb 1.
Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. Journal of Clinical Oncology. 2020;38(31):3615-3625. doi:10.1200/JCO.20.01363
27 .Jagsi R, Falchook AD, Hendrix LH, et al. Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. International Journal of Radiation Oncology - Biology - Physics. 2014 Dec 1;90(5):1001-9. doi: 10.1016/j.ijrobp.2014.09.032.
Vicini F, Shah C, Ben Wilkinson J, et al. Should ductal carcinoma-in-situ (DCIS) be removed from the ASTRO consensus panel cautionary group for off-protocol use of accelerated partial breast irradiation (APBI)? A pooled analysis of outcomes for 300 patients with DCIS treated with APBI. Annals of Surgical Oncology. 2013 Apr;20(4):1275-81. doi: 10.1245/s10434-012-2694-7. Epub 2012 Sep 29.
Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2022 Jun;20(6):691-722. doi: 10.6004/jnccn.2022.0030.
30.Stackievicz R, Paran H, Bernheim J, et al. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ. The Israel Medical Association Journal. 2010 May;12(5):290-5.
Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update Journal of Clinical Oncology. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309. Epub 2020 Jan 13.
Hird RB, Chang A, Cimmino V, et al. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer. 2006 May 15;106(10):2113-8. doi: 10.1002/cncr.21873.
Allred DC, Anderson SJ, Paik S, et al. Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24. Journal of Clinical Oncology. 30, 1268-1273(2012).DOI:10.1200/JCO.2010.34.0141
Forbes JF, Sestak I, Howell A, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0.
Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016 Feb 27;387(10021):849-56. doi: 10.1016/S0140-6736(15)01168-X.
UpToDate. Ductal carcinoma in situ: Treatment and prognosis 2025. (14.04.2025 tarihinde https://www.uptodate.com/contents/ductal-carcinoma-in-situ-treatment-and-prognosis adresinden ulaşılmıştır).
NCCN. Guidelines Version 3.2025 Ductal Carcinoma in Situ 2025. (14.04.2025 tarihinde http://www.nccn.org/professionals/physician_gls/ pdf/breast.pdf adresinden ulaşılmıştır)
